IntroductionAssociation of vitamin D, inflammation and endothelial dysfunction, beside the classic bone metabolism disorders, may explain the pathogenesis of numerous diseases associated with vitamin D deficiency. While large numbers of reports support the relationship of vitamin D with inflammation, several reports fail to confirm this relationship. Neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) are novel and inexpensive markers of inflammation that can be studied in all centers. The goal of this study was to investigate the association between 25-hydroxy vitamin D (25(OH)D) and inflammation with the novel inflammatory markers NLR and PLR.Material and methodsThis study was performed retrospectively. Results of the simultaneously performed 25(OH)D, parathyroid hormone, albumin, calcium, phosphorus, alkaline phosphatase and creatinine level measurements and complete blood count were recorded. The data of 4120 patients were included in the study.ResultsBetween vitamin D deficient and non-deficient groups there were significant differences in PLR (p < 0.001) and NLR (p = 0.001). Vitamin D had a significant negative correlation with PLR (p < 0.001) and NLR (p < 0.001). Multiple regression analysis indicated that 25(OH)D was independently and negatively correlated with PLR (OR = 0.994, 95% CI 0.991–0.998, p = 0.02).ConclusionsPlatelet-to-lymphocyte ratio and NLR were significantly associated with 25(OH)D levels, and PLR was found to be an independent predictor of 25(OH)D levels. Our study revealed an inverse association of vitamin D levels and inflammation with these inexpensive and universally available markers.
Objectives This study aimed to evaluate the current situation of
hypoparathyroid patients and to investigate the relationship between
treatment adherence and quality of life.
Study design Prospective, multicentre study.
Methods Adult patients presenting with the diagnosis of
hypoparathyroidism to 20 different endocrinology clinics were included. They
were receiving conventional therapies for hypoparathyroidism, using calcium,
active vitamin D, and magnesium. We collected data on demographic features,
disease- and treatment-related information, and results of routine
laboratory tests, treatment adherence, and presence of complications. Beck
Depression Inventory, Beck Anxiety Inventory, and Short Form-36 quality of
life assessments were administered.
Results Among the 300 patients studied, 60.7% were adherent
to their treatment, and 34.1% had complications. Anxiety and
depression scores were significantly higher in non-adherent versus
treatment-adherent patients (p<0.001 and p=0.001,
respectively). Most of the domains of quality-of-life scores were also
significantly lower in non-adherent patients. Both anxiety and depression
scores showed significant, negative correlations with serum calcium and
magnesium concentrations (r=−0.336, p<0.001
and r=−0.258, p<0.001, respectively).
Conclusions Nearly 40% of the patients were non-adherent to
conventional treatment for hypoparathyroidism, and such patients had higher
anxiety and depression scores and poorer quality of life scores.
Conventional treatment might not be sufficient to meet the needs of patients
with hypoparathyroidism. In addition to seeking new therapeutic options,
factors influencing quality of life should also be investigated and
strategies to improve treatment adherence should be developed.
All expenses of the Archives of Basic and Clinical Research are covered by the unconditional education support provided by Erzincan Culture and Education Foundation (EKEV). Archives of Basic and Clinical Research'ın giderleri, Erzincan Kültür ve Eğitim Vakfı (EKEV) tarafından sağlanan koşulsuz eğitim desteğiyle karşılanmaktadır.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.